...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy.
【24h】

Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy.

机译:调强放疗重新照射鼻咽癌。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: To evaluate the treatment outcome in patients with locally recurrent nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT). MATERIALS AND METHODS: Between October 2001 and May 2004, 31 patients with locally recurrent NPC received re-irradiation using IMRT. The rT classification distribution was 3 for rT1, 5 for rT2, 9 for rT3, and 14 for r T4. Median time from first course of radiotherapy to re-irradiation was 51 months. IMRT was performed using step-and-shoot method with nine 4-6 MV photon fields and median prescribed dose was 54 Gy (range: 50-60 Gy). Additional treatments included cisplatin-based induction chemotherapy in 68% and radiosurgery boost with a single dose which ranged from 8.5 to 12.5 Gy in 32%. Median follow-up time was 11 months. RESULTS: After re irradiation, 58% of patients had complete regression of primary tumor. One-year loco-regional progression-free, distant metastasis-free and overall survival rates were 56, 90, and 63%,respectively. Significantly better 1-year local progression-free rate was observed in rT1-3 than r T4 tumor (100 vs. 35%). Grade 3 late toxicities, mostly ototoxicity/cranial neuropathy, occurred in six patients (19%). One-year actuarial rates of late toxicities were 70% for all grades and 25% for Grade 3. CONCLUSION: Our preliminary results showed that good control of rT1-3 NPC can be achieved using IMRT with a dose between 50 and 60 Gy, whereas the outcome for r T4 tumor remained poor. Late toxicities were common but incidence of severe toxicities was relatively low.
机译:背景与目的:评价经强度调制放射治疗(IMRT)治疗的局部复发性鼻咽癌(NPC)患者的治疗结果。材料与方法:在2001年10月至2004年5月之间,有31例局部复发的鼻咽癌患者接受了IMRT再照射。 rT1的rT分类分布为3,rT2为5,rT3为9,r T4为14。从第一次放疗到再次放疗的中位时间为51个月。 IMRT使用9个4-6 MV光子场的分步拍摄法进行,中位处方剂量为54 Gy(范围:50-60 Gy)。其他治疗包括68%的基于顺铂的诱导化学疗法和32%的单剂量从8.5至12.5 Gy范围的放射外科手术强化治疗。中位随访时间为11个月。结果:重新照射后,有58%的患者原发肿瘤完全消退。一年局部无进展,无远处转移和总生存率分别为56%,90%和63%。在rT1-3中观察到的1年局部无进展率明显好于r T4肿瘤(100 vs. 35%)。 6名患者(19%)发生了3级晚期毒性,主要是耳毒性/颅神经病。所有级别的晚期毒性的一年精算率分别为70%和3%的25%。结论:我们的初步结果表明,使用IMRT剂量为50至60 Gy可以很好地控制rT1-3 NPC。 r T4肿瘤的预后仍然很差。后期毒性很常见,但严重毒性的发生率相对较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号